Vertex, Announces

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

07.08.2025 - 17:57:13

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine.

and www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

@ businesswire.com

Hol dir den Wissensvorsprung der Profis. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Trading-Empfehlungen – dreimal die Woche, direkt in dein Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr.
Jetzt anmelden.